SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is facing significant downward pressure following an earnings report that highlighted a weak outlook and slower-than-expected turnaround in the China market, triggering a wave of analyst downgrades. Community discussion is heavily polarized between investors betting on a long-term 'buy the dip' opportunity for an iconic brand and those warning of a structural decline due to increased competition and shifting consumer preferences.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is attracting heavy investor attention as the company moves its earnings report to April 1st, fueling speculation about a potential surprise and the upcoming impact of U.S. federal cannabis rescheduling. While bulls are pointing to recent beverage partnerships and potential growth in the CBD pilot program as key catalysts for a rally, bearish participants remain focused on concerns regarding share dilution and the company's management track record.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly (LLY) is trending following an FDA warning against telehealth companies for misleading marketing of compounded GLP-1 medications, a move that clarifies market expectations and increases regulatory scrutiny on the weight-loss drug space. The community is actively debating the stock's valuation, the long-term impact of potential pricing pressures, and the highly anticipated upcoming FDA approval for the company's oral obesity pill, orforglipron.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing intense speculative momentum as investors closely monitor reports of a potential acquisition, with SpaceX and Amazon frequently cited as the primary parties vying for the company's critical satellite spectrum. The community is actively debating the timing of an official announcement, particularly as Globalstar approaches a scheduled earnings call and industry observers look for signs of a strategic move to secure the company's direct-to-device infrastructure.

Mega Fortune Co., Ltd. operates as a holding company which provides information technology services. It specializes in delivering comprehensive IoT solutions and services across various industries. The firm offers low carbon property management, energy, stock and GreenTech management services. The company was founded in 2011 and is headquartered in Hong Kong.

Mega Fortune Co Ltd.

Mega Fortune Company Limited

Mega Fortune Company Limited is generating significant trading volume as traders speculate on its potential for volatile price swings common among low-float Chinese IPOs. The community is actively debating whether the stock will mirror historical patterns of massive short-term surges or succumb to typical pump-and-dump mechanics, with many monitoring its low float and share lock-up status.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is seeing intense market volatility and debate following a mixed earnings report that missed profit estimates, with investors weighing the company's long-term global expansion plans against ongoing headwinds from the challenging housing market and complex tariff impacts. The community remains deeply divided, with some traders hunting for a short-term squeeze or long-term value entry, while others express skepticism over the company's high debt levels and luxury furniture demand in the current economic climate.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is seeing heightened activity driven by its reputation as a volatile, low-float runner, with investors intensely debating whether it will repeat past parabolic short squeezes. Community discussions are heavily split between those betting on another massive upside move fueled by tight share availability and those warning of the risks inherent in the stock's speculative, pump-and-dump nature.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending due to a 14.2 billion dollar deal to repurchase a significant stake in its Ireland Fab 34 joint venture, signaling an aggressive move to regain strategic manufacturing control amid an AI-focused operational pivot. The community remains deeply divided, with some investors viewing the stock as a prime turnaround opportunity while others express significant concern over broader geopolitical instability and the company's long-term competitive position against sector peers.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors digest the commercial launch of Yartemlea and monitor the potential for near-term milestone payments from its multi-billion dollar partnership with Novo Nordisk. Community discussion remains heavily focused on the stock's significant short interest, with many retail shareholders expressing frustration over stagnant price action while others remain bullish on the long-term value of the company's pipeline and pending European regulatory developments.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is trending following the announcement of a massive multi-year AI infrastructure contract, fueling intense community speculation about its low-float potential to trigger a significant short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Axsome Inks Agreement To Obtain Exclusive Global Rights To TAK-063 From Takeda

(RTTNews) - Biopharmaceutical company Axsome Therapeutics, Inc. (AXSM) announced Wednesday that it has entered into an asset purchase agreement to obtain exclusive global rights to TAK-063 (balipodect), a novel, oral, potent, and selective phosphodiesterase 10A (PDE10A) inhibitor...

Hennion & Walsh Asset Management Inc. Cuts Stock Position in Axsome Therapeutics, Inc. $AXSM

Hennion & Walsh Asset Management Inc. cut its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 18.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 38,386 shares of the company's stock after selling 8,530 share...

Why Is Acadia (ACAD) Down 12.9% Since Last Earnings Report?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axsome Therapeutics (NASDAQ:AXSM) Raised to Strong-Buy at Truist Financial

Truist Financial upgraded Axsome Therapeutics to a "strong-buy" rating in a research note on Wednesday...

Why Is Axsome (AXSM) Down 6.6% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Guggenheim Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock

Guggenheim increased their price objective on Axsome Therapeutics from $220.00 to $245.00 and gave the company a "buy" rating in a report on Wednesday...

JPMorgan Chase & Co. Has $30.43 Million Holdings in Axsome Therapeutics, Inc. $AXSM

JPMorgan Chase & Co. boosted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 42.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 250,513 shares of the company's stock...

This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain

Key PointsSuperstring Capital Management purchased 37,433 shares of Axsome Therapeutics in the fourth quarter...

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Recommendation of "Moderate Buy" from Analysts

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) has been given an average rating of "Moderate Buy" by the nineteen research firms that are covering the firm, Marketbeat.com reports. Two...

Axsome Therapeutics, Inc. $AXSM Shares Purchased by Eventide Asset Management LLC

Eventide Asset Management LLC raised its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 2.9% during the third quarter, according to its most recent disclosure with the SEC. The...

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Current Price	$174.34
Prev Close	$169.02
Open	$170.66
Dividend Yield	0.00%
50-Day Moving Average	$172.54
Beta	0.73
Avg. Volume	624,903.80
PE Ratio	-45.75

52-Week High	$191.50
52-Week Low	$86.99
Market Capitalization	$8.65B
EPS (Annual)	-$3.68
Price to Book	97.40
Revenue Per Employee	$690,265.95

AXSM
Axsome Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AXSM News

AXSMAxsome Therapeutics Inc